Novocure announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields...
INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia ...
MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on dev...
Collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancr...
-Massive Bio, a leader in AI-enabled oncology trial matching and patient access, and Prognos Health, a provider of actionable lab data, announced a...
Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics ...
Akeso, Inc.announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome sub...
First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (Nasdaq: JANX...
- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has anno...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMO...
The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial...
BriaCell Therapeutics Corp. a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned s...
© 2026 Biopharma Boardroom. All Rights Reserved.
